Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assay

Abstract excerpt

Introduction Circulating tumor DNA (ctDNA) detection postoperatively may identify patients with urothelial cancer at a high risk of relapse. Pragmatic tools building off clinical tumor next-generation sequencing (NGS) platforms could have the potential to increase assay accessibility. Methods We evaluated the widely available Foundation Medicine comprehensive genomic profiling (CGP) platform as a source of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bladder and Urothelial Cancer Treatments
• Share to Cancer Genomics and Diagnostics
• Share to Single-cell and spatial transcriptomics